Under construction – not a live service
Sign in
Taking people in United StatesPhase 3

Letermovir (Prevymis) for CMV in Kidney and Pancreas Transplant Recipients

Key facts

Who runs it
University of Wisconsin, Madison
Where
Madison, United StatesSee the site
Trial code
Status
Recruiting
Phase
Phase 3
People taking part
90 people, planned
Started
8 Aug 2024
Expected to end
Aug 2027
Type of study
Interventional
Treatments tested
  • Letermovir
Record updated
11 June 2026

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 10 criteriaShow less

Who can take part

  • undergone kidney or simultaneous kidney/pancreas transplant
  • high-risk CMV serostatus (D+/R-) at time of transplant
  • develop CMV viremia that necessitates treatment per our institutional protocol (enrolled in the CMV stewardship monitoring initiative)
  • demonstrate proven or presumptive lack of CMI, either by CMI testing or risk factor screening
  • able to provide informed consent to participate

Who cannot take part

  • currently participating in any study involving the administration of a CMV vaccine or another CMV investigational agent
  • develop ganciclovir-resistant CMV infection
  • contraindication to letermovir or its excipients
  • unable or unwilling, in the opinion of the Investigator, to comply with the protocol
  • pregnant or breastfeeding

Where in United States

  • UW Hospital and ClinicsMadison, United StatesContact: Brad Astor, PhD (sub-investigator)Taking people

About the trial

What the trial wants to find out

This study is designed to assess how effective letermovir is in preventing recurrence of cytomegalovirus (CMV) infection in adult kidney or kidney/pancreas transplant recipients who are UW Health patients. Participants will be in the study for about 6 months.

The group in the trial

  • Letermovir for CMV in Transplant PatientsTreatment being tested

    Enrolled participants will be converted from treatment with ganciclovir derivatives to letermovir

    Treatment: Letermovir

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.
Official title
An Interventional Study of Letermovir for Secondary Prophylaxis After Treatment of Cytomegalovirus Infection in High Risk (D+/R-) Kidney and Kidney/Pancreas Transplant Recipients
Record updated
11 June 2026